Literature DB >> 22492743

Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.

Noriko Kishida1, Seiichiro Fujisaki, Masaru Yokoyama, Hironori Sato, Reiko Saito, Hideyuki Ikematsu, Hong Xu, Emi Takashita, Masato Tashiro, Shinichi Takao, Takuya Yano, Tomoko Suga, Chiharu Kawakami, Miwako Yamamoto, Keiko Kajiyama, Hiroyuki Saito, Shin'ichi Shimada, Sumi Watanabe, Satomi Aoki, Katsuya Taira, Miyako Kon, Jih-Hui Lin, Takato Odagiri.   

Abstract

The vaccine strains against influenza virus A/H3N2 for the 2010-2011 season and influenza virus B for the 2009-2010 and 2010-2011 seasons in Japan are a high-growth reassortant A/Victoria/210/2009 (X-187) strain and an egg-adapted B/Brisbane/60/2008 (Victoria lineage) strain, respectively. Hemagglutination inhibition (HI) tests with postinfection ferret antisera indicated that the antisera raised against the X-187 and egg-adapted B/Brisbane/60/2008 vaccine production strains poorly inhibited recent epidemic isolates of MDCK-grown A/H3N2 and B/Victoria lineage viruses, respectively. The low reactivity of the ferret antisera may be attributable to changes in the hemagglutinin (HA) protein of production strains during egg adaptation. To evaluate the efficacy of A/H3N2 and B vaccines, the cross-reactivities of postvaccination human serum antibodies against A/H3N2 and B/Victoria lineage epidemic isolates were assessed by a comparison of the geometric mean titers (GMTs) of HI and neutralization (NT) tests. Serum antibodies elicited by the X-187 vaccine had low cross-reactivity to both MDCK- and egg-grown A/H3N2 isolates by HI test and narrow cross-reactivity by NT test in all age groups. On the other hand, the GMTs to B viruses detected by HI test were below the marginal level, so the cross-reactivity was assessed by NT test. The serum neutralizing antibodies elicited by the B/Brisbane/60/2008 vaccine reacted well with egg-grown B viruses but exhibited remarkably low reactivity to MDCK-grown B viruses. The results of these human serological studies suggest that the influenza A/H3N2 vaccine for the 2010-2011 season and B vaccine for the 2009-2010 and 2010-2011 seasons may possess insufficient efficacy and low efficacy, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492743      PMCID: PMC3370437          DOI: 10.1128/CVI.05726-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  66 in total

Review 1.  Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.

Authors:  Brian R Murphy; Kathleen Coelingh
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

Review 2.  Force fields for protein simulations.

Authors:  Jay W Ponder; David A Case
Journal:  Adv Protein Chem       Date:  2003

3.  Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.

Authors:  I V Alymova; S Kodihalli; E A Govorkova; B Fanget; C Gerdil; R G Webster
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus.

Authors:  H Kida; L E Brown; R G Webster
Journal:  Virology       Date:  1982-10-15       Impact factor: 3.616

5.  Immunity to influenza as related to antibody levels.

Authors:  J A Morris; J A Kasel; M Saglam; V Knight; F A Loda
Journal:  N Engl J Med       Date:  1966-03-10       Impact factor: 91.245

6.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

7.  Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines.

Authors:  C W Potter; R Jennings; K Nicholson; D A Tyrrell; K G Dickinson
Journal:  J Hyg (Lond)       Date:  1977-12

8.  Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation.

Authors:  L V Gubareva; J M Wood; W J Meyer; J M Katz; J S Robertson; D Major; R G Webster
Journal:  Virology       Date:  1994-02-15       Impact factor: 3.616

9.  Prevalence of antibody to current influenza viruses and effect of vaccination on antibody response.

Authors:  M S Pereira; P Chakraverty; G C Schild; M T Coleman; W R Dowdle
Journal:  Br Med J       Date:  1972-12-23

10.  Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly.

Authors:  Hang Xie; Xianghong Jing; Xing Li; Zhengshi Lin; Ewan Plant; Olga Zoueva; Hong Yang; Zhiping Ye
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

View more
  13 in total

1.  Bringing influenza vaccines into the 21st century.

Authors:  Ethan C Settembre; Philip R Dormitzer; Rino Rappuoli
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

Review 2.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.

Authors:  Yu Bin Seo; Won Suk Choi; Jacob Lee; Joon Young Song; Hee Jin Cheong; Woo Joo Kim
Journal:  Clin Vaccine Immunol       Date:  2014-05-14

4.  IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.

Authors:  Yoshihiko Terauchi; Kaori Sano; Akira Ainai; Shinji Saito; Yuki Taga; Kiyoko Ogawa-Goto; Shin-Ichi Tamura; Takato Odagiri; Masato Tashiro; Mikiya Fujieda; Tadaki Suzuki; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

5.  Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.

Authors:  Yu Bin Seo; Jacob Lee; Joon Young Song; Hee Jung Choi; Hee Jin Cheong; Woo Joo Kim
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

6.  Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.

Authors:  Elena V Vassilieva; Haripriya Kalluri; Devin McAllister; Misha T Taherbhai; E Stein Esser; Winston P Pewin; Joanna A Pulit-Penaloza; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

7.  Differential Effects of Prior Influenza Exposures on H3N2 Cross-reactivity of Human Postvaccination Sera.

Authors:  Hang Xie; Lei Li; Zhiping Ye; Xing Li; Ewan P Plant; Olga Zoueva; Yangqing Zhao; Xianghong Jing; Zhengshi Lin; Toshiaki Kawano; Meng-Jung Chiang; Courtney L Finch; Martina Kosikova; Anding Zhang; Yanhong Zhu; Xiu-Feng Wan
Journal:  Clin Infect Dis       Date:  2017-07-15       Impact factor: 9.079

8.  Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.

Authors:  Svetlana Shcherbik; Nicholas Pearce; Irina Kiseleva; Natalie Larionova; Larisa Rudenko; Xiyan Xu; David E Wentworth; Tatiana Bousse
Journal:  J Virol Methods       Date:  2015-10-28       Impact factor: 2.014

9.  H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps.

Authors:  Hang Xie; Xiu-Feng Wan; Zhiping Ye; Ewan P Plant; Yangqing Zhao; Yifei Xu; Xing Li; Courtney Finch; Nan Zhao; Toshiaki Kawano; Olga Zoueva; Meng-Jung Chiang; Xianghong Jing; Zhengshi Lin; Anding Zhang; Yanhong Zhu
Journal:  Sci Rep       Date:  2015-10-16       Impact factor: 4.379

10.  Antigenic characterization of influenza viruses produced using synthetic DNA and novel backbones.

Authors:  Pirada Suphaphiphat; Lynne Whittaker; Ivna De Souza; Rodney S Daniels; Philip R Dormitzer; John W McCauley; Ethan C Settembre
Journal:  Vaccine       Date:  2016-05-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.